(NASDAQ: FBLG) Fibrobiologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.24%.
Fibrobiologics's earnings in 2026 is -$18,646,000.On average, 6 Wall Street analysts forecast FBLG's earnings for 2026 to be -$844,596, with the lowest FBLG earnings forecast at -$960,521, and the highest FBLG earnings forecast at -$603,283. On average, 6 Wall Street analysts forecast FBLG's earnings for 2027 to be -$922,330, with the lowest FBLG earnings forecast at -$1,258,614, and the highest FBLG earnings forecast at -$567,796.
In 2028, FBLG is forecast to generate -$982,489 in earnings, with the lowest earnings forecast at -$1,656,071 and the highest earnings forecast at -$674,257.